Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors

Recruiting now · Phase 3

Conditions studied: Locally Advanced Solid Tumor

In brief

This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.

Key facts

Study ID

NCT06658353

Run by

Jiangsu vcare pharmaceutical technology co., LTD

People needed

54

Starts

2025-03-17

Expected to finish

2026-12-30

Last updated by the study team

2026-07-27

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures；
• Male or female, age ≥12 years old;

You may not qualify if…

• Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures);
• Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator);
• Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.

Where it is running

• Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.